"TAARgeting Addiction"-The Alamo Bears Witness to Another Revolution. An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference

Drug and Alcohol Dependence

Volumn 159, Issue , 2016, Pages 9-16

  Grandy, David K ^a   Miller, Gregory M ^b   Li, Jun Xu ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Dopamine D2 receptor; Dopamine transporter; Methamphetamine; Parkinson's disease; Psychostimulant addiction; Schizophrenia; Trace amine associated receptor 1

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DRUGS USED IN THE TREATMENT OF ADDICTION; METHAMPHETAMINE; N (3 ETHOXY PHENYL) 4 PYRROLIDIN 1 YL 3 TRIFLUOROMETHYL BENZAMIDE; PROTEIN KINASE C; RECEPTOR; RO 5203648; RO 5263397; TRACE AMINE ASSOCIATED RECEPTOR 1 PROTEIN; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT; G PROTEIN COUPLED RECEPTOR; TRACE AMINE-ASSOCIATED RECEPTOR 1;

BINDING AFFINITY; CELLULAR DISTRIBUTION; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SEEKING BEHAVIOR; FIRING RATE; HEALTH CARE ORGANIZATION; HUMAN; LOCOMOTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REINFORCEMENT; RELAPSE; REVIEW; REWARD; SIGNAL TRANSDUCTION; ADDICTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM;

ANIMALS; BEHAVIOR, ADDICTIVE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84955054806     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.11.014     Document Type: Review

References (78)

1. Achat-Mendes C., Lynch L.J., Sullivan K.A., Vallender E.J., Miller G.M. Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1. Pharmacol. Biochem. Behav 2012, 101:201-207.
2. Berry M.D. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev. Recent Clin. Trials 2007, 2:3-19.
3. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., Durkin M.M., Lakhlani P.P., Bonini J.A., Pathirana S., Boyle N., Pu X., Kouranova E., Lichtblau H., Ochoa F.Y., Branchek T.A., Gerald C. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8966-8971.
4. Boulton A.A., Wu P.H., Philips S. Binding of some primary aromatic amines to certain rat brain particulate fractions. Can. J. Biochem. 1972, 50:1210-1218.
5. Bradaia A., Trube G., Stalder H., Norcross R.D., Ozmen L., Wettstein J.G., Pinard A., Buchy D., Gassmann M., Hoener M.C., Bettler B. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20081-20086.
6. Broadley K.J., Akhtar Anwar M., Herbert A.A., Fehler M., Jones E.M., Davies W.E., Kidd E.J., Ford W.R. Effects of dietary amines on the gut and its vasculature. Br. J. Nutr. 2009, 101:1645-1652.
7. Budygin E.A., Brodie M.S., Sotnikova T.D., Mateo Y., John C.E., Cyr M., Gainetdinov R.R., Jones S.R. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7781-7786.
8. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., Darland T., Suchland K.L., Pasumamula S., Kennedy J.L., Olson S.B., Magenis R.E., Amara S.G., Grandy D.K. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001, 60:1181-1188.
9. Carboni E., Spielewoy C., Vacca C., Nosten-Bertrand M., Giros B., Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 2001, 21:1-4.
10. Cisneros I.E., Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology 2014, 85:499-507.
11. Cotter R., Pei Y., Mus L., Harmeier A., Gainetdinov R.R., Hoener M.C., Canales J.J. The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects. Front. Neurosci. 2015, 9:39.
12. D'Andrea G., Terrazzino S., Fortin D., Farruggio A., Rinaldi L., Leon A. HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes. Neurosci. Lett. 2003, 346:89-92.
13. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5274-52781.
14. Di Cara B., Maggio R., Aloisi G., Rivet J.M., Lundius E.G., Yoshitake T., Svenningsson P., Brocco M., Gobert A., De Groote L., Cistarelli L., Veiga S., De Montrion C., Rodriguez M., Galizzi J.P., Lockhart B.P., Cogé F., Boutin J.A., Vayer P., Verdouw P.M., Groenink L., Millan M.J. Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J. Neurosci. 2011, 31:16928-16940.
15. El-Ghundi M., George S.R., Drago J., Fletcher P.J., Fan T., Nguyen T., Liu C., Sibley D.R., Westphal H., O'Dowd B.F. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur. J. Pharmacol. 1998, 353:149-158.
16. Eriksen J., Rasmussen S.G., Rasmussen T.N., Vaegter C.B., Cha J.H., Zou M.F., Newman A.H., Gether U. Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J. Neurosci. 2009, 29:6794-6808.
17. Espinoza S., Salahpour A., Masri B., Sotnikova T.D., Messa M., Barak L.S., Caron M.G., Gainetdinov R.R. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol. 2011, 80:416-425.
18. Espinoza S., Ghisi V., Emanuele M., Leo D., Sukhanov I., Sotnikova T.D., Chieregatti E., Gainetdinov R.R. Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. Neuropharmacology 2015, 93:308-313.
19. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
20. Frascarelli S., Ghelardoni S., Chiellini G., Vargiu R., Ronca-Testoni S., Scanlan T.S., Grandy D.K., Zucchi R. Cardiac effects of trace amines: pharmacological characterization of trace amine-associated receptors. Eur. J. Pharmacol. 2008, 587:231-236.
21. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
22. Grandy D.K. A G protein-coupled receptor mechanism of action distinguishes methamphetamine from cocaine. Abstract #175.03/OO6 2014, Society for Neuroscience Annual Meeting, Washington, DC.
23. Grandy D.K. Trace amine-associated receptor 1-family archetype or iconoclast?. Pharmacol. Ther. 2007, 116:355-390.
24. Harmeier A., Obermueller S., Meyer C.A., Revel F.G., Buchy D., Chaboz S., Dernick G., Wettstein J.G., Iglesias A., Rolink A., Bettler B., Hoener M.C. Trace amine-associated receptor 1 activation silences GSK3(signaling of TAAR1 and D2R heteromers. Eur. Neuropsychopharmacol. 2015, (Aug). [Epub ahead of print] pii: S0924-977X(15)00264-3. 10.1016/j.euroneuro.2015.08.011.
25. Hart M.E., Suchland K.L., Miyakawa M., Bunzow J.R., Grandy D.K., Scanlan T.S. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J. Med. Chem. 2006, 49:1101-1112.
26. Heidbreder C.A., Andreoli M., Marcon C., Hutcheson D.M., Gardner E.L., Ashby C.R. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict. Biol. 2007, 12:35-50.
27. Hiroi N., White N.M. The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. Brain Res. 1991, 552:141-152.
28. Hursh S.R., Galuska C.M., Winger G., Woods J.H. The economics of drug abuse: a quantitative assessment of drug demand. Mol. Interv. 2005, 5:20-28.
29. Jing L., Zhang Y., Li J.X. Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats. Int. J. Neuropsychopharmacol. 2014, 18.
30. Jing L., Li J.X. Trace amine-associated receptor 1: a promising target for the treatment of psychostimulant addiction. Eur. J. Pharmacol. 2015, 761:345-352.
31. Kim K.A., Zastrow M. Old drugs learn new tricks: insights from mammalian trace amine receptors. Mol. Pharmacol. 2001, 60:1165-1167.
32. Ledonne A., Federici M., Giustizieri M., Pessia M., Imbrici P., Millan M.J., Bernardi G., Mercuri N.B. Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells. Br. J. Pharmacol. 2010, 160:1509-1520.
33. Leo D., Mus L., Espinoza S., Hoener M.C., Sotnikova T.D., Gainetdinov R.R. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology 2014, 81:283-291.
34. Lindemann L., Meyer C.A., Jeanneau K., Bradaia A., Ozmen L., Bluethmann H., Bettler B., Wettstein J.G., Borroni E., Moreau J.L., Hoener M.C. Trace amine-associated receptor 1 modulates dopaminergic activity. J. Pharmacol. Exp. Ther. 2008, 324:948-956.
35. Liu X., Grandy D.K., Janowsky A. Ractopamine, a livestock feed additive, is a full agonist at trace amine-associated receptor 1. J. Pharmacol. Exp. Ther. 2014, 350:124-129.
36. Lynch L.J., Sullivan K.A., Vallender E.J., Rowlett J.K., Platt D.M., Miller G.M. Trace amine associated receptor 1 modulates behavioral effects of ethanol. Subst. Abuse 2013, 7:117-126.
37. Miller G.M. The emerging role of trace amine associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J. Neurochem. 2011, 116:164-176.
38. Miller G.M. Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1). J. Med. Chem. 2012, 55:1809-1814. (2012).
39. Miller G.M., Verrico C.D., Jassen A., Konar M., Yang H., Panas H., Bahn M., Johnson R., Madras B.K. Primate trace amine receptor 1 modulation by the dopamine transporter. J. Pharmacol. Exp. Ther. 2005, 313:983-994.
40. Nelson D.A., Tolbert M.D., Singh S.J., Bost K.L. Expression of neuronal trace amine-associated receptor (TAAR) mRNAs in leukocytes. J. Neuroimmunol. 2007, 192:21-30.
41. Panas M.W., Xie Z., Panas H.N., Hoener M.C., Vallender E.J., Miller G.M. Trace amine associated receptor 1 signaling in activated lymphocytes. J. Neuroimmune. Pharmacol. 2012, 7:866-876.
42. Pei Y., Lee J., Leo D., Gainetdinov R.R., Hoener M.C., Canales J.J. Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. Neuropsychopharmacology 2014, 39:2299-2308.
43. Pei Y., Mortas P., Hoener M.C., Canales J.J. Selective activation of the trace amine-associated receptor 1 decreases cocaine's reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 63:70-75.
44. Premont R.T., Gainetdinov R.R., Caron M.G. Following the trace of elusive amines. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9474-9475.
45. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T., Niznik H.B. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 1998, 30:79-87.
46. Reese E.A., Bunzow J.R., Arttamangkul S., Sonders M.S., Grandy D.K. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J. Pharmacol. Exp. Ther. 2007, 321:178-186.
47. Revel F.G., Moreau J.L., Gainetdinov R.R., Bradaia A., Sotnikova T.D., Mory R., Durkin S., Zbinden K.G., Norcross R., Meyer C.A., Metzler V., Chaboz S., Ozmen L., Trube G., Pouzet B., Bettler B., Caron M.G., Wettstein J.G., Hoener M.C. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8485-8490.
48. Revel F.G., Moreau J.L., Gainetdinov R.R., Ferragud A., Velázquez-Sánchez C., Sotnikova T.D., Morairty S.R., Harmeier A., Groebke Zbinden K., Norcross R.D., Bradaia A., Kilduff T.S., Biemans B., Pouzet B., Caron M.G., Canales J.J., Wallace T.L., Wettstein J.G., Hoener M.C. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 2012, 72:934-942.
49. Revel F.G., Meyer C.A., Bradaia A., Jeanneau K., Calcagno E., André C.B., Haenggi M., Miss M.T., Galley G., Norcross R.D., Invernizzi R.W., Wettstein J.G., Moreau J.L., Hoener M.C. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 2012, 37:2580-2592.
50. Revel F.G., Moreau J.L., Pouzet B., Mory R., Bradaia A., Buchy D., Metzler V., Chaboz S., Groebke Zbinden K., Galley G., Norcross R.D., Tuerck D., Bruns A., Morairty S.R., Kilduff T.S., Wallace T.L., Risterucci C., Wettstein J.G., Hoener M.C. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 2013, 18:543-556.
51. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1998, 1:132-137.
52. Sabelli H.C., Vazquez A.J., Flavin D. Behavioral and electrophysiological effects of phenylethanolamine and 2-phenylethylamine. Psychopharmacologia 1975, 42:117-125.
53. Salahpour A., Espinoza S., Masri B., Lam V., Barak L.S., Gainetdinov R.R. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front. Endocrinol. 2012, 3:1-9.
54. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., Frascarelli S., Crossley D.A., Bunzow J.R., Ronca-Testoni S., Lin E.T., Hatton D., Zucchi R., Grandy D.K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10:638-642.
55. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
56. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
57. Snead A.N., Santos M.S., Seal R.P., Miyakawa M., Edwards R.H., Scanlan T.S. Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem. Biol. 2007, 2:390-398.
58. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Revay R., Lesch K.P., Murphy D.L., Uhl G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7699-7704.
59. Sotnikova T.D., Budygin E.A., Jones S.R., Dykstra L.A., Caron M.G., Gainetdinov R.R. Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J. Neurochem. 2004, 91:362-373.
60. Spielewoy C., Biala G., Roubert C., Hamon M., Betancur C., Giros B. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology 2001, 159:2-9.
61. Sriram U., Cenna J.M., Haldar B., Fernandes N.C., Razmpour R., Fan S., Ramirez S.H., Potula R. Methamphetamine induces trace amine-associated receptor 1 (TAAR1) expression in human T lymphocytes: role in immunomodulation. J. Leukocyte Biol. 2015, [Epub ahead of print] pii: jlb.4A0814-395RR.
62. Stalder H., Hoener M.C., Norcross R.D. Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773). Bioorg. Med. Chem. Lett. 2011, 21:1227-1231.
63. Szumska J., Qatato M., Rehders M., Führer D., Biebermann H., Grandy D.K., Köhrle J., Brix K. Trace amine-associated receptor 1 localization at the apical plasma membrane domain of Fisher rat thyroid epithelial cells is confined to cilia. Eur. Thyroid. J. 2015, 10.1159/000434717; epub ahead of print.
64. Thorn D.A., Jing L., Qiu Y., Gancarz-Kausch A.M., Galuska C.M., Dietz D.M., Zhang Y., Li J.X. Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats. Neuropsychopharmacology 2014, 39:2309-2316.
65. Thorn D.A., Zhang C., Zhang Y., Li J.X. The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats. Neurosci. Lett. 2014, 566:67-71.
66. Urs N.M., Daigle T.L., Caron M.G. A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 2011, 36:551-558.
67. Vezina P. Sensitization, drug addiction and psychopathology in animals and humans. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1553-1555.
68. Wainscott D.B., Little S.P., Yin T., Tu Y., Rocco V.P., He J.X., Nelson D.L. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. J. Pharmacol. Exp. Ther. 2007, 320:475-485.
69. Wasik A.M., Millan M.J., Scanlan T., Barnes N.M., Gordon J. Evidence for functional trace amine associated receptor-1 in normal and malignant B cells. Leuk. Res. 2012, 36:245-249.
70. Wise R.A. Action of drugs of abuse on brain reward systems. Pharmacol. Biochem. Behav. 1980, 13(Suppl. 1):213-223.
71. Wolf M.E., Mosnaim A.D. Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacol. 1983, 14:385-390.
72. Wolinsky T.D., Swanson C.J., Smith K.E., Zhong H., Borowsky B., Seeman P., Branchek T., Gerald C.P. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007, 6:628-639.
73. Xie Z., Miller G.M. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J. Pharmacol. Exp. Ther. 2007, 321:128-136.
74. Xie Z., Miller G.M. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. J. Pharmacol. Exp. Ther. 2008, 325:617-628.
75. Xie Z., Miller G.M. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J. Pharmacol. Exp. Ther. 2009, 330:316-325.
76. Xie Z., Vallender E.J., Yu N., Kirstein S.L., Yang H., Bahn M.E., Westmoreland S.V., Miller G.M. Cloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic association. J. Neurosci. Res. 2008, 86:3435-3446.
77. Xie Z., Westmoreland S.V., Bahn M.E., Chen G.L., Yang H., Vallender E.J., Yao W.D., Madras B.K., Miller G.M. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J. Pharmacol. Exp. Ther. 2007, 321:116-127.
78. Xie Z., Westmoreland S.V., Miller G.M. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J. Pharmacol. Exp. Ther. 2008, 325:629-640.